Acetylon Pharmaceuticals has initiated a Phase I/IIa clinical trial of ACY-1215, an oral Class II histone deacetylase inhibitor, in adults with relapsed and relapsed/refractory multiple myeloma.
The Phase Ia and Ib portions will evaluate the maximum tolerated dose of ACY-1215 as a monotherapy or in combination with bortezomib and dexamethasone, followed by up to five additional sequential cycles of treatment.
Go deeper with GlobalData
The Phase IIa portion is designed to determine the objective response rate to ACY-1215 in combination dose for up to six 21-day cycles.
The clinical trial is being conducted by Acetylon in partnership with The Leukaemia & Lymphoma Society.
See Also:
